CEA Antibody / Carcinoembryonic Antigen

Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT (1),Prediluted IHC only format: incubate for 30 min at RT (2)

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CEA antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

Human full-length recombinant protein was used as the immunogen for this CEA antibody.

This CEA antibody is available for research use only.

Cytoplasmic and luminal surface

Protein G affinity chromatography

Human

P06731